A Phase IV, Randomized, Open-Label, Comparative, Multicenter Study to Assess the Safety and Efficiancy of Induction Agents Alemtuzumab (Campath 1H), Basiliximab (Simulect) or Rabbit Anti-Thymocyte Globulin (Thymoglobulin) in Combination with Tacrolimus

Grants and Contracts Details

StatusFinished
Effective start/end date1/22/0611/30/07

Funding

  • Astellas Pharma US Inc: $3,260.00